Aarti Pharmalabs Limited
Aarti Pharmalabs Limited is an Indian pharmaceutical manufacturer producing APIs, intermediates, CDMO drug substances, synthetic caffeine, and xanthine derivatives across six plants, serving 500+ global generic pharma, innovator biotech, beverage, nutraceutical, and chemical industry customers in regulated markets.
- Company typePublic
- Founded2019
- HeadquartersMumbai, India
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Aarti Pharmalabs Limited does
Aarti Pharmalabs Limited (APL) is an Indian pharmaceutical and nutraceutical manufacturer that operates six manufacturing plants and two R&D centres, producing Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, xanthine derivatives including synthetic caffeine, sulphur-based acid and allied products, and offering Contract Development and Manufacturing Organization (CDMO) services. Incorporated in 2019 and demerged from Aarti Industries Limited in 2022, APL is publicly listed on NSE (AARTIPHARM) and BSE (543748). The company serves four distinct customer segments: global generic pharmaceutical companies requiring APIs and intermediates with regulatory documentation, innovator pharma and biotech firms needing CDMO services for NCE development from clinical Phases I through commercial launch, beverages and nutraceutical companies sourcing caffeine and xanthine derivatives, and chemical industry buyers of sulphur-based alkylating agents.
APL's technical foundation rests on proprietary process chemistry capabilities including flow chemistry, continuous hydrogenation, photochemistry, high-pressure reactions (up to 100 kg/cm²), cryogenic reactions (down to -100°C), biocatalysis, and HPAPI manufacturing at OEL levels of 1-10 µg/m³. The company holds 40 US Drug Master Files and 20 Certificates of Suitability from EDQM, with 15+ years of regulatory compliance across USFDA, EU GMP, KFDA, COFEPRIS, and WHO GMP. APL controls 800+ KL of reactor volume and produces 3,600+ MT of caffeine annually, commanding 15-20% of global caffeine supply as the world's only integrated non-Chinese caffeine manufacturer and approximately 80% of India's domestic caffeine demand.
The business model is B2B and project-based: revenue is generated through quote-driven sales of APIs, intermediates, and chemicals with multi-year contracts for products carrying regulatory documentation (USDMF, EDMF, CEP), and through professional services fees for CDMO engagements across clinical and commercial phases. Distribution is predominantly direct export to regulated markets (USA, EU, Japan) with selective use of chemical distributors for acid and allied products. Backward integration into raw materials is a central cost strategy, reducing Chinese supply dependency. APL's FY26 consolidated revenue was Rs 1,819.4 crore with net profit of Rs 174.7 crore, marking a notable decline from FY25. Leadership is provided by Chairman Rashesh C. Gogri, Vice Chairperson & Managing Director Hetal Gogri Gala, and Managing Director Narendra Salvi, with the Gogri family retaining significant board influence following the 2022 demerger.
Aarti Pharmalabs Limited firmographics
Firmographics- Name
- Aarti Pharmalabs Limited
- Legal name
- Aarti Pharmalabs Limited
- Website
- https://aartipharmalabs.com
- Company type
- Public
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Aarti Pharmalabs Limited is an Indian pharmaceutical manufacturer producing APIs, intermediates, CDMO drug substances, synthetic caffeine, and xanthine derivatives across six plants, serving 500+ global generic pharma, innovator biotech, beverage, nutraceutical, and chemical industry customers in regulated markets.
- Ownership category
- akta.pro rank
Aarti Pharmalabs Limited industry classification
Industry- Product category
- Active Pharmaceutical Ingredients (APIs)
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Industrial Organic Chemicals (2860)
- akta.pro primary industry
- Small-Molecule API & Intermediates CDMO (HLAGABAA)
- akta.pro secondary industries
- Small-Molecule API Commercial Manufacturing (HLAGAHAB), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
Keywords
Where Aarti Pharmalabs Limited is headquartered
LocationHeadquarters
- HQ city
- Mumbai
- HQ country
- India
- HQ region
- Asia
Offices10 records
Markets served
Aarti Pharmalabs Limited business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Infrastructure, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- API Manufacturing & Sales: Manufacture and sale of Active Pharmaceutical Ingredients including cardiovascular, anti-asthmatic, anti-cancer, CNS agents, and other therapeutic categories. Revenue generated from direct product sales to pharmaceutical companies globally.
- Pharmaceutical Intermediates: Custom synthesis of intermediates for pharmaceutical clients, including regulated starting materials (RSM) and key starting materials (KSM) for API and NCE production.
- CDMO Services: Contract Development and Manufacturing Organization services for drug substance/NCE development and manufacturing for innovator pharma and biotech companies, covering Ph-I/II/III, launch, and commercial phases.
- Caffeine Products: Production and sale of caffeine anhydrous and caffeine granules for beverages, nutraceuticals, and pharmaceutical industries. Annual capacity up to 4000 MT.
- Xanthine Derivatives: Manufacture of theophylline, aminophylline, etofylline, and other xanthine derivatives for pharmaceutical, beverage, and nutraceutical industries.
- Acid & Allied Products: Sulphur-based chemicals including sulphuric acid, sulphur trioxide, oleum, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulphonate for dyes, pharmaceuticals, and perfumery industries.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | API products with varying regulatory documentation support |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Aarti Pharmalabs Limited product offering
Product offeringCore offering
Aarti Pharmalabs Limited manufactures and supplies Active Pharmaceutical Ingredients (APIs) across cardiovascular, anti-asthmatic, anti-cancer, CNS, and anti-diabetic therapeutic categories, alongside pharmaceutical intermediates, regulatory starting materials (RSM), and xanthine derivatives including synthetic caffeine. The company also offers Contract Development and Manufacturing Organization (CDMO) services covering clinical Ph-I/II/III through commercial manufacturing for innovator pharma and biotech customers, supported by two R&D centres and six manufacturing facilities accredited by USFDA, EU GMP, EDQM, KFDA, COFEPRIS, and WHO GMP.
Product overview
Aarti Pharmalabs Limited operates as a manufacturer of Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, and xanthine derivatives, with integrated CDMO (Contract Development and Manufacturing Organization) services. The product portfolio includes: APIs across therapeutic categories such as cardiovascular (Ramipril, Quinapril), anti-asthmatic (Budesonide, Salmeterol), anti-cancer (Bicalutamide, Ifosfamide), CNS agents (Venlafaxine, Quetiapine), and anti-diabetic (Sitagliptin, Canagliflozin); custom pharmaceutical intermediates for major drug molecules; CDMO services for drug substance development through clinical to commercial phases; Caffeine products (Anhydrous and Granules) with 4000 MT annual capacity; Xanthine derivatives including Theophylline and Etofylline; and Acid & Allied products like Sulfuric Acid and Dimethyl Sulfate. The company has backward integration capabilities and serves regulated markets including USA, EU, and Japan.
Differentiator
Problem solved
Functional benefit
Products and services
- Active Pharmaceutical Ingredients (APIs) Manufacture and supply of generic Active Pharmaceutical Ingredients across cardiovascular, anti-asthmatic, anti-cancer, CNS, anti-diabetic and other therapeutic categories, manufactured at USFDA and EU GMP accredited facilities for global generic pharmaceutical companies.
- Pharmaceutical Intermediates Customized pharmaceutical intermediates for API manufacturing — including intermediates for Abemaciclib, Apixaban, Canagliflozin and other major drug molecules — offered at development, pilot, and commercial stages for pharmaceutical manufacturers.
- CDMO Services Contract Development and Manufacturing Organization services for drug substance / New Chemical Entity (NCE) development and manufacturing from clinical Ph-I/II/III through launch and commercial phases, offering HPAPI/cytotoxic handling, high-pressure, cryogenic, photochemistry, and flow chemistry capabilities for innovator pharma and biotech companies.
- Caffeine (Anhydrous and Granules) Manufacture and sale of synthetic Caffeine Anhydrous and Caffeine Anhydrous Granules for the pharmaceutical, beverage, and nutraceutical industries, with combined annual capacity up to 4,000 Metric Tons across Unit-III and Unit-V Tarapur, marking the company as the world's only integrated non-Chinese caffeine manufacturer.
- Xanthine Derivatives Manufacture of xanthine derivatives including Theophylline, Aminophylline, DMAU, Etofylline, and Dimethyl Urea for pharmaceutical and nutraceutical applications, with combined xanthine-derivatives capacity of 3,600 MT per annum.
- Acid & Allied Products Sulphur-based chemicals including Sulfur Trioxide, Sulfuric Acid, Oleum variants, Dimethyl Sulfate, Diethyl Sulfate, and Sodium Vinyl Sulfonate supplied to dyes, pharmaceuticals, and perfumery industries.
Quantifiable outcome
- 15-20% of global caffeine supply as world's only integrated non-Chinese caffeine manufacturer
- +4 more outcomes
Companies that use Aarti Pharmalabs Limited
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles4 records
Aarti Pharmalabs Limited technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
Aarti Pharmalabs Limited partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Neighbourhood and multi-speciality hospitalssupportAgreements with neighbourhood and multi-speciality hospitals for ensuring employees receive medical care as part of occupational health infrastructure. Also involves hiring of specialist physicians for employee health programs.
Scale indicators20 records
Recent moves8 records
Expansion highlights4 records
Aarti Pharmalabs Limited competitors and assessment
Company assessmentDirect peers
- Divi's Laboratories: Leading Indian API and intermediates manufacturer with global CDMO presence. Directly comparable to Aarti Pharmalabs in small-molecule API manufacturing, custom synthesis, and generics supply to regulated markets.
- Laurus Labs: Indian API and CDMO company with strong generics franchise and growing contract development services for innovator pharma. Comparable in API manufacturing scale and CDMO positioning to Aarti Pharmalabs.
- Suven Pharmaceuticals: Indian CDMO focused on small molecule NCE development and manufacturing for global innovator pharma. Closely comparable to Aarti Pharmalabs' CDMO business model and customer base (biotech/innovator pharma).
- Jubilant Pharmova: Indian pharmaceutical company with CDMO services (Jubilant Biosys, Contract Manufacturing) and API manufacturing. Competes with Aarti Pharmalabs in CDMO and radiopharmaceuticals-adjacent segments.
- Syngene International: India-based contract research and manufacturing organization offering drug substance development and manufacturing services. Comparable as a direct CDMO peer for innovator pharma/biotech customers.
- Piramal Pharma Solutions: Global CDMO offering API development, manufacturing, and complex chemistry services including HPAPIs. Comparable CDMO service portfolio and customer overlap with Aarti Pharmalabs' innovator pharma/biotech segment.
- Granules India: Indian API and pharmaceutical formulations manufacturer with focus on generic APIs. Comparable in generic API manufacturing scale and vertically integrated operations.
- CARBOGEN AMCIS (Dishman): Swiss-headquartered CDMO with Indian operations, specializing in API development, highly potent APIs, and complex chemistry. Comparable CDMO capabilities and HPAPI expertise.
Broad incumbents
- Aurobindo Pharma: Large Indian generic pharmaceutical company with significant API manufacturing operations serving global markets. Overlaps with Aarti Pharmalabs on generic APIs but operates a much broader finished dosage portfolio.
- Dr. Reddy's Laboratories: Major Indian pharma with API manufacturing business and active pharmaceutical services division. Comparable on generic API supply and growing CDMO services, though much larger and more diversified.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Aarti Pharmalabs Limited compliance and trust
Trust signalCompliance12 records
Aarti Pharmalabs Limited financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aarti Pharmalabs Limited leadership team
Management profileNumber of profiles
Profiles15 records
Aarti Pharmalabs Limited funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aarti Pharmalabs Limited M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aarti Pharmalabs Limited
What does Aarti Pharmalabs Limited do?
Aarti Pharmalabs Limited manufactures and supplies Active Pharmaceutical Ingredients (APIs) across cardiovascular, anti-asthmatic, anti-cancer, CNS, and anti-diabetic therapeutic categories, alongside pharmaceutical intermediates, regulatory starting materials (RSM), and xanthine derivatives including synthetic caffeine. The company also offers Contract Development and Manufacturing Organization (CDMO) services covering clinical Ph-I/II/III through commercial manufacturing for innovator pharma and biotech customers, supported by two R&D centres and six manufacturing facilities accredited by USFDA, EU GMP, EDQM, KFDA, COFEPRIS, and WHO GMP.
Is Aarti Pharmalabs Limited a public or private company?
Aarti Pharmalabs Limited is a public company. It is classified as public and is currently operating.
When was Aarti Pharmalabs Limited founded?
Aarti Pharmalabs Limited was founded in 2019. It employs 1,001 to 5,000 people.
Where is Aarti Pharmalabs Limited based?
Aarti Pharmalabs Limited is headquartered in Mumbai, India, in the Asia region.
How does Aarti Pharmalabs Limited make money?
Six revenue lines are on record. API Manufacturing & Sales are the primary driver. The others are pharmaceutical Intermediates, CDMO Services, caffeine Products, xanthine Derivatives and acid & Allied Products.
Who are Aarti Pharmalabs Limited's main competitors?
Direct peers on record are Divi's Laboratories, Laurus Labs, Suven Pharmaceuticals, Jubilant Pharmova, Syngene International, Piramal Pharma Solutions, Granules India and CARBOGEN AMCIS (Dishman). Broad incumbents are Aurobindo Pharma and Dr. Reddy's Laboratories.
Does Aarti Pharmalabs Limited have an API?
No public API is recorded for Aarti Pharmalabs Limited.
What industry is Aarti Pharmalabs Limited in?
Aarti Pharmalabs Limited's product category is Active Pharmaceutical Ingredients (APIs). Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGAHAB, Small-Molecule API Commercial Manufacturing. Its NAICS code is 3254 and its SIC code is 2834.